Pharmacokinetics and bioavailability of the flavonol quercetin in humans

International Journal of Clinical Pharmacology and Therapeutics

Volumn 37, Issue 5, 1999, Pages 219-233

  Graefe, E U ^a   Derendorf, H ^b   Veit, M ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b Department of Pharmacotherapy and Translational Research   (United States)

Author keywords

Absorption; Bioavailability; Flavonoids; Metabolism; Pharmacokinetics; Quercetin

Indexed keywords

FLAVONOID; QUERCETIN;

CANCER CHEMOTHERAPY; CARDIOVASCULAR DISEASE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; METHODOLOGY; NONHUMAN; ORAL DRUG ADMINISTRATION; REVIEW; STEADY STATE;

EID: 0032964858     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Ames BN, Gold LS 1995 The causes and prevention of cancer: gaining perspective. Environ Health Perspect 105 (Suppl 4): 865-873
2. Aziz AA, Edwards CA, Lean ME, Crozier A 1998 Absorption and excretion of conjugated flavonols, including quercetin-4′-0-β-glucoside and isorhamnetin-4′-0-β-glucoside by human volunteers after consumption of onions. Free Rad Res 29: 251-269
3. Baba S, Furuta T, Horie M, Nakagawa H 1981 Studies on drug metabolism by use of isotopes XXVI: Determination of urinary metabolites of rutin in humans. J Pharm Sci 70: 780-782
4. Block G, Patterson B, Subar A 1992 Fruit, vegetables, and cancer prevention: a review of the epidemiological evidence. Nutr Cancer 18: 1-29
5. Bokkenheuser VD, Winter J, Cohen BI, O'Rourke S, Mosbach EH 1987 Hydrolysis of dietary flavonoid glycosides by strains of intestinal bacteroides from humans. Biochem J 248: 953-956
6. Booth AN, Williams RT 1963 Dehydroxylation of catechol acids by intestinal contents. Biochem J 88: 66p-67p
7. Boulton DW 1998 personal communication.
8. Boulton DW, Walle UK, Walle T 1998 Extensive binding of the bioflavonoid quercetin to human plasma proteins. J Pharm Pharmacol 50: 1-8
9. Brown S, Griffiths LA 1983 New metabolites of the naturally-occurring mutagen, quercetin, the pro-mutagen, rutin and of taxifolin. Experientia 39: 198-200
10. Conquer JA, Maiani G, Azzini E, Raguzzini A, Holub BJ 1998 Supplementation with quercetin markedly increases plasma quercetin concentration without effect on selected risk factors for heart disease in healthy subjects. J Nutr 128: 593-597
11. Crespy V, Manach C, Morand C, Besson C Demigne C, Remesy C1998 Intestinal absorption and metabolism of quercetin. XIXth International Conference on Polyphenols. Lille, France, 75
12. Day AJ, DuPont MS, Ridley S, Rhodes M, Rhodes MJC, Morgan MRA, Williamson, G 1998 Deglycosylation of flavonoid and isoflavonoid glycosides by human small intestine and liver β-glucosidase activity. FEBS letters accepted for publication August 1998
13. De Smet PA, Brouwers JR 1997 Pharmacokinetic evaluation of herbal remedies. Basic introduction, applicability, current status and regulatory needs. Clin Pharmacokinet 32: 427-436
14. de Vries JH, Janssen PL, Hollman PC, van Staveren WA, Katan MB 1997 Consumption of quercetin and kaempferol in free-living subjects eating a variety of diets. Cancer Lett 114: 141-144
15. Deprez S, Buffnoir S, Scalbert A, Rolando C 1997 Isotopic labelling of proamhocyanidins. Analusis Magazine 25: M43-46
16. Derendorf H, Garrett ER 1987 Pharmakokinetik. Wissenschaftliche Verlagsgesellschaft, Stuttgart
17. Drieu K, Moreau J-P, Eck C-R, McCabe J, Skinner S 1985 Animal distribution and preliminary human kinetic studies of the flavonoid fraction of a standardized Ginkgo biloba extract (GBE 761). In: Farkas L, Gabor M, Kallay F (eds) Flavonoids and Bioflavonoids. Akademiai Kiado, Budapest, pp 351-359
18. Ferry DR, Smith A, Malkhandi J, Fyfe DW, deTakats PG, Anderson D, Baker J, Kerr DJ 1996 Phase I Clinical Trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res 2: 659-668
19. Formica JV, Regelson W 1995 Review of the biology of Quercetin and related bioflavonoids. Food Chem Toxicol 33: 1061-1080
20. Gee JM, Dupont MS, Rhodes MJC, Johnson IT 1998 Quercetin glucosides interact with the intestinal glucose transport pathway. Free Rad Biol Med 25: 19-25
21. Gibaldi M, Perrier D 1982 Pharmacokinetics. Marcel Dekker, Inc., New York
22. Graefe U, Derendorf H, Veit M 1997 Urinary metabolites of flavonoids in humans after application of a crude extract from Equisetum arvense L. American Association of Pharmaceutical Scientists. Boston, USA. Pharm Res 14: S386
23. Griffiths LA 1982 Mammalian metabolism of flavonoids. In: Harborne JB, Mabry TJ (eds) The Flavonoids: Advances in Research. Chapman and Hall, London
24. Gross M, Pfeiffer M, Martini M, Campbell D, Slavin J, Potter J 1996 The quantitation of metabolites of quercetin flavonols in human urine. Cancer Epidemiol Biomarkers Prev 5: 711-20
25. Gugler R, Leschik M, Dengler HJ 1975 Disposition of quercetin in man after single oral and intravenous doses. Eur J Clin Pharmacol 9: 229-234
26. Hatcher JF, Bryan GT 1985 Factors affecting the mutagenic activity of quercetin for Salmonella typhimurium TA98: metal ions, antioxidants and pH. Mutat Res 148: 13-23
27. Heilmann J, Merfort I 1998 Aktueller Kenntnisstand zum Metabolismus von Flavonoiden: I. Resorption und Metabolismus von Flavonolen. Pharmazie in unserer Zeit 27:58-65
28. Hertog MG, Hollman PC, Katan MB 1992 Content of potentially anticarcinogenic flavonoids of 28 vegetables and 9 fruits commonly consumed in the Netherlands. J Agric Food Chem 40: 2379-2383
29. Hertog MG 1996a Epidemiological evidence on potential health properties of flavonoids. Proc Nutr Soc 55: 385-397
30. Hertog MG, Bueno de Mesquita HB, Fehily AM, Sweetnam PM, Elwood PC, Kromhout D 1996b Fruit and vegetable consumption and cancer mortality in the Caerphilly Study. Cancer Epidemiol Biomarkers Prev 5: 673-677
31. Hertog MG, Feskens EJ, Hollman PC, Katan MB, Kromhout D 1993a Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet 342: 1007-1011
32. Hertog MG, Hollman PC, Katan MB, Kromhout D 1993b Intake of potentially anticarcinogenic flavonoids and their determinants in adults in The Netherlands. Nutr Cancer 20: 21-29
33. Hertog MG, Kromhout D, Aravanis C, Blackburn H, Buzina R, Fidanza F, Giampaoli S, Jansen A, Menotti A, Nedeljkovic S 1995 Flavonoid intake and longterm risk of coronary heart disease and cancer in the seven countries study (published erratum appears in Arch Intern Med 1995 Jun 12, 155: 1184). Arch Intern Med 155: 381-386
34. Hertog MG, Sweetnam PM, Fehily AM, Elwood PC, Kromhout D 1997 Antioxidant flavonols and ischemic heart disease in a Welsh population of men: the Caerphilly Study. Am J Clin Nutr 05: 1489-1494
35. Hollman PC, de Vries JH, van Leeuwen SD, Mengelers MJ, Katan MB 1995 Absorption of dietary quercetin glycosides and quercetin in healthy ileostomy volunteers. Am J Clin Nutr 62: 1276-1282
36. Hollman PC, Hertog MG, Katan MB 1996a Role of dietary flavonoids in protection against cancer and coronary heart disease. Biochem Soc Trans 24: 785-789
37. Hollman PC, v d Gaag M, Mengelers MJ, van Trijp JM, de Vries JH, Katan MB 1996b Absorption and disposition kinetics of the dietary antioxidant quercetin in man. Free Radic Biol Med 21: 703-707
38. Hollman PC, van Trijp JM, Buysman MN, v.d. Gaag MS, Mengelers MJ, de Vries JH, Katan MB 1997a Relative bioavailability of the antioxidant flavonoid quercetin from various foods in man. FEBS Lett 418: 152-156
39. Hollman PC, van Trijp JM, Mengelers MJ, de Vries JH, Katan MB 1997b Bioavailability of the dietary antioxidant flavonol quercetin in man. Cancer Lett 114: 139-140
40. Ihme N, Kiesewetter H, Jung F, Hoffmann KH, Birk A, Muller A, Grutzner KI 1996 Leg oedema protection from a buckwheat herb tea in patients with chronic venous insufficiency: a single-centre, randomised, double-blind, placebo-controlled clinical trial. Eur J Clin Pharmacol 50: 443-447
41. Janssen PLTMK, Mensink RP, Cox FJJ, Harryvan JL, Hovenier R, Hollman PCH, Katan MB 1998 Effects of the flavonoids quercetin and apigenin on the hemostasis in healthy volunteers: results from an in vitro an a dietary supplement study. Am J Clin Nutr 67: 255-262
42. Justesen U, Knuthsen P, Leth T 1997 Determination of plant polyphenols in Danish foodstuffs by HPLCUV and LC-MS detection. Cancer Lett 114: 165-167
43. Keli SO, Hertog MG, Feskens EJ, Kromhout D 1996 Dietary flavonoids, antioxidant vitamins, and incidence of stroke: the Zutphen study. Arch Intern Med 156: 637-642
44. Kim DH, Jung EA, Sohng IS, Han JA, Kim TH, Han MJ 1998 Intestinal bacterial metabolism of flavonoids and its relation to some biological activities. Arch Pharmacol Res 21: 17-23
45. Knekt P, Jarvinen R, Reunanen A, Maatela J 1996 Flavonoid intake and coronary mortality in Finland: a cohort study (see comments). Br Med J 312: 478-481
46. Manach C, Morand C, Crespy V, Demigne C, Texier O, Regerat F, Remesy C 1998 Quercetin is recovered in human plasma as conjugated derivatives which retain antioxidant properties. FEBS Lett 426: 331-336
47. Manach C, Morand C, Demigne C, Texier O, Regerat F, Remesy C 1997 Bioavailability of rutin and quencetin in rats. FEBS Lett 409: 12-16
48. Manach C, Morand C, Texier O, Favier ML, Agullo G, Demigne C, Regerat F, Remesy C 1995 Quercetin metabolites in plasma of rats fed diets containing rutin or quercetin. J Nutr 125: 1911-1922
49. Merfort I, Heilmann J, Weiss M, Pietta P, Gardana C 1996 Radical scavenger activity of three flavonoid metabolites studied by inhibition of chemiluminescence in human PMNs. Planta Med 62: 289-292
50. Middleton E, Kandaswami C 1993 The impact of plant flavonoids on mammalian biology: Implications for immunity, inflammation and cancer. Chapman and Hall, London
51. Murgu L, Dobrescu D, Andronescu S, Jacobas S 1978 Study of the bioavailability in man of rutoside from some pharmaceutical products. Farmacia Bucharest 26: 149-154
52. Nieder M 1991 Pharmakokinelik der Ginkgo-Flavonoide im Plasma. Münch Med Wochenschr 133: S61-S62
53. Nielsen SE, Kall M, Justesen U, Schou A, Dragsted LO 1997 Human absorption and excretion of flavonoids after broccoli consumption. Cancer Lett 114: 173-174
54. Noteborn HPJM, Jansen E, Benito S, Mengelers MJB 1997 Oral absorption and metabolism of quercetin and sugar-conjugated derivatives in specific transport systems. Cancer Lett 114: 175-177
55. Olthof MR, Hollman PC, Katan MB 1998 Absorption and excretion of quercetin glucosides in man. XIXth International Conference on Polyphenols. Lille, France, 69
56. Pace-Asciak CR, Hahn S, Diamandis EP, Soleas G, Goldberg DM 1995 The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin Chim Acta 235: 207-219
57. Paganga G, Rice Evans CA 1997 The identification of flavonoids as glycosides in human plasma. FEBS Lett 401: 78-82
58. Peter H, Fisel J, Wasser W 1966 On the pharmacology of the active ingredients of Ginkgo biloba. Arzneimittelforschung 16: 719-725
59. Pietta PG, Gardana C, Mauri PL 1997 Identification of Ginkgo biloba flavonol metabolites after oral administration to humans. J Chromatogr B 693: 249-255
60. Piskula MK, Terao J 1998 Quercetin's solubility affects its accumulation in rat plasma after oral administration. J Agric Food Chem 46:4313-4317
61. Price KR, Bacon JR, Rhodes MJC 1997 Effect of storage and domestic processing on the content and composition of flavonol glucosides in onion (Allium cepa). J Agric Food Chem 45: 938-942
62. Rice-Evans CA, Miller NJ, Paganga G 1997 Antioxidant properties of phenolic compounds. Trends Plant Sci 2: 152-159
63. Rimm ER, Katan MB, Ascherio A, Stampfer MJ, Willett WC 1996 Relation between intake of flavonoids and risk for coronary heart disease in male health professionals. Arch Intern Med 125: 384-389
64. Sawai Y, Kohsaka K, Nishiyama Y, Ando K 1987 Serum concentrations of rutoside metabolites after oral administration of a rutoside formulation to humans. Arzneimittelforschung 37: 729-732
65. Scheline RR 1968 Drug metabolism by intestinal microorganisms. J Pharm Sci 57: 2021-2037
66. Scheline RR 1991 CRC Handbook of mammalian metabolism of plant compounds. CRC Press, Boca Raton
67. Schilcher H, Hagels H 1996 Zur Pharmakokinetik und zum Metabolismus von Flavonoiden. In: Loew D, Rietbrock N (eds) Phytopharmaka II: Forschung und klinische Anwendung. Steinkopff, Darmstadt, pp 55-62
68. Schramm DD, German JB 1998 Potential effects of flavonoids on the etiology of vascular disease. J Nutr Biochem 9: 560-566
69. Steinmetz KA, Potter JD 1991 Vegetables, fruit and cancer. I. Epidemiology. Cancer Cause Control 2: 325-357
70. 14C] quercetin in the ACI rat. Jpn J Exp Med 53: 41-50
71. Walgren RA, Walle UK, Walle T 1998 Transepithelial absorption of quercetin and quercetin glucosides across the CACO-2 human intestinal cell line. Clin Pharmacol Ther 63: 212
72. Walle T, Wilson AA, Walle UK 1998 Bioavailability of the chemopreventive agent resveratrol compared to quercetin using human cell models. Clin Pharmacol Ther 63: 149
73. Winter J, Moore LH, Dowell VR Jr, Bokkenheuser VD 1989 C-ring cleavage of flavonoids by human intestinal bacteria. Appl Environ Microbiol 55: 1203-1208